ReviewJournal of translational medicine2025
Mechanistic insights into the role of RNA demethylase ALKBH5 in malignant tumor therapy.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- ALKBH5 Positively Regulates BMP2 to Influence Endometrial Decidualization in Recurrent Spontaneous Abortion.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- CRM-1 Aggravates Stroke Injury by Promoting BANF1-Mediated Unfolded Protein Response Through Inducing Nuclear Export of ALKBH5.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- ALKBH4 confers ferroptosis resistance and drives tumorigenesis via dysregulation of GPX4 in breast cancer cells.In vitro cellular & developmental biology. Animal · 2026Article
- The role of non-coding RNAs in the pathogenesis of migraine: from molecular insights to potential biomarkers.Frontiers in neurology · 2026Review
- Gut microbiota-derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
m6A RNA methylation represents the most prevalent epitranscriptomic modification and modulates diverse dimensions of RNA metabolism. As a dynamic and reversible post-transcriptional mark, m6A is broadly distributed across multiple RNA types, including mRNA, ribosomal RNA (rRNA), microRNA (miRNA), long non-coding RNA (lncRNA), circular RNA (circRNA), and small nuclear RNA (snRNA). ALKB homolog 5 (ALKBH5), an m6A demethylase, has been extensively characterized for its involvement in tumorigenesis and progression through the removal of methylated modification from RNA, subsequently influencing RNA metabolism and gene expression regulation. A growing body of evidence indicates that ALKBH5 contributes to the therapeutic response in various cancers. Its aberrant expression is frequently observed across malignancies, where it modulates oncoprotein levels, promotes tumor initiation, and accelerates cancer cell proliferation, progression, and metastasis. Nevertheless, its implications for therapy responsiveness and the emergence of drug resistance remain poorly understood. This review centers on ALKBH5-mediated regulatory pathways and mechanisms in the contexts of chemotherapy, radiotherapy, and immunotherapy in malignancies, while also evaluating the therapeutic relevance of ALKBH5 as a molecular target and the potential of its pharmacological inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.